Table 2.

Univariate analysis univariate analysis of potential prognostic factors

Prognostic factors	N = 31 (percentage)	5-year OS	p Value	5 Year-DFS	p Value
Gender
Male	22 (71%)	46.3%	0.8	29.1%	0.354
Female	9 (29%)	55.6%		25.4%
Age
< 50	22 (71%)	61.4%	0.05	24.4%	0.97
≥ 50	9 (29%)	22.2%		–
Histology
KSCC	6 (19.4%)	80%	0.08	–	0.983
NKDC	11 (35.4%)	27%		40.9%
NKUC	14 (45.2%)	57.1%		32.1%
T-classification
T2	5 (16.1%)	53.3%	0.518	–	0.078
T3	18 (58.1%)	53.8%		36.7%
T4	8 (25.8%)	0%		0%
Stage
III	20 (64.5%)	55.2%	0.133	40.2%	0.02*
IV A	11(35.4%)	24.5%		0%
NACT
Yes	19 (61.3%)	56.5%	0.169	33.7%	0.094
No	12 (38.7%)	33.3%		21.8%
RT dose
≥ 66 Gy	22 (71%)	54.7%	0.441	23.1%	0.896
< 66 Gy	9 (29%)	33.3%		–
Concurrent chemotherapy drug
Cisplatin	25 (80.6%)	53%	0.232	29.2%	0.26
Carboplatin paclitaxel	6 (19.4%)	22.2%		20%